- High-dose vitamin D supplementation (5000 IU daily) for 6 months significantly improved peripheral insulin sensitivity and ß-cell function in individuals at high risk for diabetes or newly diagnosed type 2 diabetes (T2D).
Why this matters
- Findings suggest that vitamin D supplementation may reduce metabolic deterioration in individuals at high risk for diabetes or newly diagnosed T2D.
- Patients at a high risk of diabetes or with newly diagnosed T2D (n=96) were randomly assigned to receive either vitamin D3 5000 IU or placebo for 6 months.
- Peripheral insulin sensitivity (M value using a 2-hour hyperinsulinemic-euglycemic clamp), indices of insulin sensitivity, insulin secretion, ß-cell function (disposition index: M value x insulinogenic index) and other measures were evaluated at baseline and 6 months.
- Funding: Johnson & Johnson and others.
- Treatment group vs placebo group had significantly higher vitamin D level at:
- 3 months (122.9 vs 52.2 nmol/L; P<.001 and>
- 6 months (127.6 vs 51.8 nmol/L; P<.001>
- M value (mean change, 0.92; 95% CI, 0.24-1.59 vs −0.03; 95% CI, −0.73 to 0.67; P=.009), and
- disposition index (mean change, 267.0; 95% CI, −343.4 to 877.4 vs −55.5; 95% CI, −696.3 to 585.3; P=.039).
- Single-centre study.
- Only Caucasians were included restricting generalisability to other ethnic groups.